Genmab — November 2018
-
Cassiopeia kom ikke med https://ash.confex.com/ash/2018/webprogram/Session13723.html
-
Nordea gik da godt nok fra salg til køb..måske Novod må overgive sig..:-)
-
-
-
Det undrede mig lidt, at Genmab ville have Q&A en uge efter regnskab denne gang. Deres timing fejler ikke noget.
-
New small trial : Phase 2 Study for the Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone as 2nd Line Therapy in Multiple Myeloma Patients (DARIA) https://clinicaltrials.gov/ct2/show/NCT03746652?term=daratumumab+OR+ofatumumab+OR+tisotumab+OR+arzerra+OR+darzalex&lupd_s=11%2F20%2F2018&rank=1
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind